HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarins

This article was originally published in The Rose Sheet

Executive Summary

Largest ad effort this fall will focus on Clarins Extra Firming Eye Contour Serum and Cream. One- and two-page spots will break in September and run through the fall in beauty and fashion books, including Vogue, Elle and Vanity Fair. Recommended for morning use, the serum contains a protein and polysaccharide complex to promote cell renewal, vitamin E, pineapple and papaya extracts to "drain and decongest the lymphatic system" and mica and titanium to diffuse light. Extra Firming Eye Contour Cream for night use contains chicory extract to "hydrate, moisturize and revitalize," butcher's broom extract to "reduce the signs of fatigue" and a cocktail of noctoferrine, vitamin C and vitamin E to prevent free radical formation. The cream and serum join the Extra Firming collection targeted to women over 35. Both products are housed in 1.7 oz. beige pump bottles and will bow in September for $42.50 apiece...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel